RxDoctor Payments Data

Adam Bowman, MD

Ophthalmology · Salt Lake City, UTNPI 1184846131

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (37.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Amgen at 37.7% of the total. Reporting peaked in 2022 at $1,914 and has fallen 98.9% since, to $20 in 2025.

$4,617in general payments, 2019–2025

Across 36 payments — averaging $128.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • Johnson & Johnson Surgical Vision, Inc.$2K
  • AbbVie$204
  • Alcon$179
  • Genentech USA, Inc.$151
  • Regeneron Healthcare Solutions, Inc.$146
  • plus $680 from 9 others

What the payments were for

  • Speaking & faculty fees$1,74038%
  • Travel & lodging$1,15025%
  • Food & beverage$1,70737%
  • Gifts$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,617 in reported general payments places this provider in the 80th percentile of 191 ophthalmology providers in Utah.

See all ophthalmology providers in Utah

Medicare billing

Part B allowed, 2024
$253,066
Medicare patients
522
Services billed
3,272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine47$56,830
LumiganBimatoprost43$31,364
Restasis MultidoseCyclosporine13$8,897
IlevroNepafenac16$6,192
CombiganBrimonidine Tartrate/Timolol14$5,819
Latanoprost366$4,833
Prednisolone Acetate112$3,807
Fluorometholone54$3,319
Gatifloxacin40$2,319
Bromfenac Sodium16$1,998
MoxifloxacinMoxifloxacin Hcl40$1,204
Brimonidine Tartrate15$935
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat35$495
Timolol Maleate43$435
Dorzolamide Hcl14$242

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Restasis Multidose, Combigan$204$102,910117 claims
NovartisIlevro$57$6,19216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 191 ophthalmology providers in Utah.

Other ophthalmology in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →